Copyright
©2010 Baishideng. All rights reserved.
World J Diabetes. Jul 15, 2010; 1(3): 99-100
Published online Jul 15, 2010. doi: 10.4239/wjd.v1.i3.99
Published online Jul 15, 2010. doi: 10.4239/wjd.v1.i3.99
Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes
Hidekatsu Yanai, Yoshinori Masui, Reo Yoshikawa, Junwa Kunimatsu, Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan
Hiroshi Kaneko, Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan
Author contributions: Yanai H and Kaneko H contributed to the conception, writing and editing of the paper; Masui Y, Yoshikawa R and Kunimatsu J treated the patient presented in the paper and contributed to data collection.
Correspondence to: Hidekatsu Yanai, MD, PhD, FACP, Department of Internal Medicine, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba 272-8516, Japan. dyanai@hospk.ncgm.go.jp
Telephone: +81-47-3733501 Fax: +81-47-3721858
Received: April 20, 2010
Revised: June 22, 2010
Accepted: June 29, 2010
Published online: July 15, 2010
Revised: June 22, 2010
Accepted: June 29, 2010
Published online: July 15, 2010
Abstract
The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 inhibitor, showing that the DPP-4 inhibitors may be an effective and safe oral anti-diabetic drug for steroid-induced diabetes.